Amersham Report issue

For profit Phase 2 Phase 3
Founded: Amersham United Kingdom (1946)
Status: Acquired by General Electric (2004) → now Danaher (2019)

Organization Overview

First Clinical Trial
2003
NCT00156884
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Amersham Health

Active Ingredients

Drugs in Phase 3 Trials (1)

omega-3 fatty acids (Omacor) (1 trial)

Drugs in Phase 2 Trials (2)

cisplatin (platinol) (1 trial)

strontium-89 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Prostatic Neoplasms (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3